Amryt Pharma said on February 28 the U.S. Food and Drug Administration declined to approve the company’s drug for the treatment of a group of rare skin diseases called epidermolysis bullosa.
The U.S. Food and Drug Administration approved MC2 Therapeutics’ Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older.
Pfizer’s oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, continues to post strong clinical trial results as a treatment for atopic dermatitis.
CURE Pharmaceutical, an innovative drug delivery and development company, signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products.
Realm Therapeutics opted to discontinue all drug development programs and is considering a potential sale of the Malvern, Pa.-based company following a clinical trial failure with the atopic dermatitis treatment PR022.
Foamix Pharmaceuticals Ltd.’s lead drug for treating moderate-to-severe acne met the main goals of the company’s third late-stage study, sending its shares up 57 percent in extended trading.
The FDA approved Mylan’s Estradiol Vaginal Cream USP 0.01%, the first generic version of Allergan’s Estrace.
Aclaris Therapeutics Inc.’s drug to treat a common type of skin growth called seborrheic keratoses received FDA clearance.
Mylan N.V. announced an agreement to acquire the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings LLC for $950 million in cash at closing.